


PHARMACEUTICAL 2021

Synaptogenix Inc. Rank 392 of 409





PHARMACEUTICAL 2021

Synaptogenix Inc. Rank 392 of 409

The relative strengths and weaknesses of Synaptogenix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Synaptogenix Inc. compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Synaptogenix Inc. is the variable Net Income, reducing the Economic Capital Ratio by 663% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,098%, being 743% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	6,729
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,612
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,728
Other Liabilities	0
Other Net Income	153
Property and Equipment	22
Research and Development	3,069
Revenues	0
Selling, General and Administrative Expense	8,059

Output Variable	Value in 1000 USD
Assets	6,751
Liabilities	1,612
Expenses	12,856
Stockholders Equity	5,139
Net Income	-12,703
Comprehensive Net Income	-12,703
Economic Capital Ratio	-1,098%